Comparison different concentration of ropivacaine used in interscalene brachial plexus block combined with general anesthesia for arthroscopic shoulder surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035647

Enrollment

Unknown

Registered

2020-08-15

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder arthroscopic surgery

Interventions

Group A:0.25% ropivacaine 20ml brachial plexus block

Group B: 0.375% ropivacaine 20ml brachial plexus block

Group C:0.5% ropivacaine 20ml brachial plexus block

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 60 patients who underwent arthroscopic shoulder surgery in our hospital were selected; 2. Patients with ASA grade I or II; 3. Patients aged 18-65 years; 4. Patients with body mass index <= 30kg / m2; 5. Men and women are not limited.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cardiovascular and cerebrovascular diseases; 2. Patients with orthostatic hypotension history; 3. Patients with nervous system or mental illness; 4. Patients with hearing and visual impairment; 5. Patients with severe liver disease; 6. Pregnant women.

Design outcomes

Primary

Measure	Time frame
systolic pressure;diastolic pressure;heart rate;Postoperative analgesia duration;Recovery time of motor block;	—

Secondary

Measure	Time frame
Atropine dosage;Ephedrine dosage;	—

Countries

China

Contacts

Public ContactLina Yang

Sichuan Academy of Medical Sciences, Sichuan people's Hospital

605033376@qq.com+86 15928522804

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026